Stent retrievers

Solitaire™ X revascularization device

<p>The Solitaire™ X revascularization device is designed for effective clot retrieval during thrombectomies for acute ischemic stroke (AIS) patients.</p>

Ordering information
Contact a representative

Features

Reliable clot engagement

Conform to anatomy with wall apposition and dynamic clot integration†,4,5

  • Maintains consistent cell size and structure over varying vessel diameters6,†
  • Provides multiple planes of contact to integrate with the clot, even double layering in smaller vessels†,7

Percent overlap by vessel diameter†,5

This chart shows the different vessel diameters available in the Solitaire™ X revascularization device to accommodate therapeutic needs.

Accurate capture

Visualize accuracy with real-time imagery

  • Meaningful visibility with real-time visualization of the radiopaque markers
  • Evaluate clot composition through body marker integration into the clot
  • Visualize the expansion and compression of the stent to help identify clot characteristics8
This image shows an X-ray of a soft clot and the Solitaire™ X revascularization device
This image shows an X-ray of a hard clot and the Solitaire™ X revascularization device.

Images courtesy of Dr. Alejandro Tomasello Weitz

Minimal vessel disruption

Encapsulate the clot without damaging the wall†,9

Differentiated radial outward force promotes clot and vessel wall contact during retrieval with the optimal amount of radial force.†,10

This graph shows the differentiated outward force of Solitaire™ X device at 3x20 diamater/ROF.
This graph shows the differentiated outward force of Solitaire™ X device at 4x40 diamater/ROF.
This graph shows the differentiated outward force of Solitaire™ X device at 6x40 diamater/ROF.

Clinical evidence

Optimize outcomes by minimizing the number of passes.11–13

A large real-world patient cohort demonstrated a first pass effect (FPE) rate of 40.5% and a modified FPE (mFPE) rate of 58.9% across patients treated with the Solitaire™ device.‡,14

Achieve the clinical outcomes you expect.

A large real-world patient cohort demonstrated the following results with the Solitaire™ device.15

87.9%

Successful reperfusion

modified Thrombolysis in Cerebral Infarction (mTICI) 2b-3, core-lab adjudicated

56.5%

modified Rankin Scale (mRS) 0–2 at 90 days

1.4%

symptomatic Intracranial
Hemorrhage (sICH)

Ordering information

United States only

Item number   Vessel diameter range (mm) Stent diameter (mm) Minimum micro catheter inside diameter (in / mm) Distal markers Proximal markers Body markers spacing (mm) Usable length (mm)
SFR4-3-20-10 1.5–3.0 3 0.017 / 0.43 3 1 10 20
SFR4-3-40-10 1.5–3.0 3 0.017 / 0.43 3 1 10 40
SFR4-4-20-05 1.5–4.0 4 0.021 / 0.53 3 1 5 20
SFR4-4-20-10 1.5–4.0 4 0.021 / 0.53 3 1 10 20
SFR4-4-40-10 1.5–4.0 4 0.021 / 0.53 3 1 10 40
SFR4-6-20-10 2.0–5.5 6 0.021 / 0.53 4 1 10 20
SFR4-6-24-06 2.0–5.5 6 0.021 / 0.53 4 1 6 24
SFR4-6-40-10 2.0–5.5 6 0.021 / 0.53 4 1 10 40

Non-U.S. countries

Item number   Vessel diameter range (mm) Stent diameter (mm) Minimum micro catheter inside diameter (in / mm) Distal markers Proximal markers Body markers spacing (mm) Usable length (mm)
SFR4-3-20-10 1.0–3.0 3 0.017 / 0.43 3 1 10 20
SFR4-3-40-10 1.0–3.0 3 0.017 / 0.43 3 1 10 40
SFR4-4-20-05 2.0–4.0 4 0.021 / 0.53 3 1 5 20
SFR4-4-20-10 2.0–4.0 4 0.021 / 0.53 3 1 10 20
SFR4-4-40-10 2.0–4.0 4 0.021 / 0.53 3 1 10 40
SFR4-6-20-10 2.0–5.5 6 0.021 / 0.53 4 1 10 20
SFR4-6-24-06 2.0–5.5 6 0.021 / 0.53 4 1 6 24
SFR4-6-40-10 2.0–5.5 6 0.021 / 0.53 4 1 10 40

Resources

† Based on bench testing results. Bench testing may not be representative of actual clinical performance.

‡ FPE defined as mTICI2c/3; modified FPE defined as mTICI 2b-3.

  1. Medtronic data on file. Solitaire Literature Review, includes Solitaire FR, Solitaire 2, Solitaire Platinum, Solitaire X, August 2022.
  2. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: A meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387(10029):1723–1731.
  3. Data on file; TR-NV12692A.

  1. Data on file; TR07-128B.
  2. Data on file; TR-NV13807A, TR-NV15666A, D00419703D, D00324045A.
  3. Data on file; TR-NV12554A.
  4. Data on file; TR-NV13807A, D00419703D.
  5. Tomasello A. The best of both worlds: Combination therapy for ischemic stroke. Oral presentation at: International Stroke Conference; February 9, 2022; New Orleans, LA.
  6. Data on file; D00188173B.
  7. Data on file; D00419703C.
  8. García-Tornel Á, Requena M, Rubiera M, et al. When to stop [published correction appears in Stroke. 2020 Jun;51(6):e118]. Stroke. 2019;50(7):1781–1788.
  9. Zaidat OO, Castonguay AC, Linfante I, et al. First pass effect: A new measure for stroke thrombectomy devices. Stroke. 2018;49(3):660–666.
  10. Flottmann F, Leischner H, Broocks G, et al. Recanalization rate per retrieval attempt in mechanical thrombectomy for acute ischemic stroke. Stroke. 2018;49(10):2523–2525.
  11. Jadhav AP, Desai SM, Zaidat OO, et al. First pass effect with neurothrombectomy for acute ischemic stroke: Analysis of the systematic evaluation of patients treated with stroke devices for acute ischemic stroke registry. Stroke. 2022;53(2):e30–e32. 
  12. Mueller-Kronast NH, Zaidat OO, Froehler MT, et al. Systematic evaluation of patients treated with neurothrombectomy devices for acute ischemic stroke: primary results of the STRATIS registry. Stroke. 2017;48(10):2760–2768.